Artelo Biosciences, Inc.
ARTL
$7.20
$0.11021.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.03M | 4.12M | 3.90M | 4.05M | 4.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.90M | 10.11M | 9.54M | 10.96M | 10.23M |
| Operating Income | -9.90M | -10.11M | -9.54M | -10.96M | -10.23M |
| Income Before Tax | -9.72M | -9.83M | -9.12M | -10.44M | -9.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.72 | -9.83 | -9.12 | -10.44 | -9.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.72M | -9.83M | -9.12M | -10.44M | -9.60M |
| EBIT | -9.90M | -10.11M | -9.54M | -10.96M | -10.23M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -20.92 | -21.30 | -19.93 | -23.29 | -21.94 |
| Normalized Basic EPS | -13.31 | -13.69 | -13.03 | -15.28 | -14.61 |
| EPS Diluted | -20.92 | -21.30 | -19.93 | -23.29 | -21.94 |
| Normalized Diluted EPS | -13.31 | -13.69 | -13.03 | -15.28 | -14.61 |
| Average Basic Shares Outstanding | 15.16M | 15.06M | 14.97M | 14.65M | 14.21M |
| Average Diluted Shares Outstanding | 15.16M | 15.06M | 14.97M | 14.65M | 14.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |